87results about "Colon cancer vaccine" patented technology

The invention is relative to novel means of systemic or mucosal vaccinial therapy against some cancers, viral infections and allergy which are provided by the invention under the form of a family of composite superimmunogenic compounds for bifunctional vaccinial use able to induce an immune response raised towards two distinct targets, respectively, the causal pathogenic antigenic structure, on the one hand, and locally produced factors responsible for a subsequent immunotoxic or neoangiogenic stroma disorder, on the other hand.

Disclosed are novel compositions, methods and vaccines, which upon administration to a patient suffering from a melanoma, colon carcinoma tumor or breast cancer, postpone and / or reduce the need for chemotherapy treatment, slow the progression of or eliminate the tumor and / or alleviate the symptoms of the tumor. The compositions comprise stressed colon carcinoma, melanoma or breast cancer cells, preferably autologous such cells.

The present invention relates to the field of treatment of tumor, and especially to a composition comprising a plasmodium, a treatment method and an application thereof. The composition of the present invention has therapeutic effects on colorectal carcinoma, lung carcinoma, breast carcinoma, gastric carcinoma and hepatic carcinoma etc., can inhibit the growth of tumor and prolong the life of the tumor patients, whereas has no therapeutic effect on melanoma and lymphoma; meanwhile, the present invention describes that the long-term plasmodium infection has better therapeutic effect on tumors, and the plasmodium immunotherapy of the present invention does not take the fever time as a course standard when treating tumors, but should be used to extend the duration of plasmodium infection as much as possible until the progression of tumors can be controlled under the premise of protecting the organ functions and life safety of the patients.

The invention provides a carrier assembly carrying a gene element combination, a recipient cell library, a preparation and screening method and an application, the recipient cell library is formed byfusing cells and the carrier assembly, and the carrier assembly at least carries three gene elements, respectively a plurality of first gene elements encoding one or more idiotypic synNotch receptors,respectively; a second gene element carrying one or more gene loops; a third gene element encoding one or more idiotypic chimeric antigen receptors. Wherein, when the first genetic element encodes one idiotypic synNotch receptor, the third genetic element must encode at least three idiotypic chimeric antigen receptors, and when the third genetic element encodes one idiotypic chimeric antigen receptor, the first genetic element must encode three idiotypic synNotch receptors. The gene loop is pre-programmed, a regulatory homeopathic factor is combined with a transcription factor, upon activation of the synNotch receptor encoded by the first gene element, the chimeric antigen receptor encoded by the third gene element is controllably expressed.

Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and / or prevention of cancer with at least partial inflammatory basis.

The invention discloses a double-chimeric antigen receptor, a T cell and a construction method and an application thereof, which belong to the field of cellular immunotherapy of tumors. The inventionspecifically relates to a specific structure and a construction method of the double chimeric antigen receptor T cell (dCAR-T cell), and preliminarily discusses the in-vivo and in-vitro activity of the dCAR-T cell. The selected tumor-associated antigens are mesothelin and carcino-embryonic antigens, and researches show that the two tumor antigens can be simultaneously expressed on the surface of asolid tumor, such as pancreatic cancer. The invention discloses an antigen receptor. The in-vitro and in-vivo tests prove that the constructed dCAR-T cell can be permanently and effectively activatedonly under the condition that two antigens are simultaneously recognized, and has efficient anti-tumor activity, so that a specific tumor killing function can be exerted, and the application of CAR-Tcell immunotherapy is improved.

The invention discloses an ROBO1 CAR-NK cell carrying a suicide gene as well as a preparation method and application of the ROBO1 CAR-NK cell. In order to improve the safety and controllability of theCAR-NK therapy, a suicide gene switch element is integrated into a genome through a lentiviral transfection technology on the basis of the current ROBO1 CAR-NK cell to form the CAR-NK with the suicide gene. By adding the suicide gene, the CAR-NK cells can be better controlled, and the clinical safety is further improved.

The invention discloses a humanized antibody and application thereof, the humanized antibody comprises a heavy chain variable region and a light chain variable region, and can specifically target a CH1 structural domain 162 site sialylated epitope of IgG, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO. 1, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO. 2. The humanized antibody can effectively inhibit the growth, invasion and suspension growth ability of tumor cells, has an obvious anti-tumor effect, and also can inhibit the activation of a c-Met / Wnt signal channel and an FAK signal channel of the tumor cells.

The invention provides a monocyte and a macrophage for expressing a chemokine receptor with solid tumor directional chemotactic ability, and preparation and application thereof, and relates to the field of biotechnology. The invention provides a macrophage, the macrophage overexpresses the chemokine receptor, the macrophage has the ability of chemotactic migration to a solid tumor and remarkable effects of chemotactic migration to the tumor and infiltration, the specific killing efficiency and utilization rate of adoptively transplanted macrophage can be improved, and non-specific immune attack to normal tissues is reduced. The invention provides a preparation method of macrophages, which comprises the following steps: constructing a lentivirus expression system containing a chemokine receptor gene, integrating the chemokine receptor gene into pluripotent stem cells or mononuclear macrophages by using the lentivirus expression system, performing induced differentiation to obtain the macrophages, and the macrophages can stably overexpress the chemokine receptor for a long time.

The invention discloses a chimeric antigen receptor of a cell for targeted expression of Claudin 18.2 (CLDN 18.2), and particularly discloses a chimeric antigen receptor with an amino acid sequence as shown in SEQ ID NO.14. The chimeric antigen receptor comprises a Claudin 18.2-targeted single-chain antibody, a hinge region, a transmembrane structural domain and an intracellular signal structural domain. The Claudin 18.2-targeted chimeric antigen receptor disclosed by the invention can achieve effective and specific targeted expression of malignant cells (such as tumor cells) of the Claudin 18.2 surface antigen, so that a more efficient method with fewer side effects and adverse reactions is provided for treating some tumors expressing the Claudin 18.2 surface antigen.

The invention relates to immunotherapy of a mammalian subject by exposing the immune response cells of the subject to a nucleic acid construct encoding at least one hCG immunogenic epitope or precursor thereof such that the nucleic acid construct is taken up and processed by the immune response cells. The invention further relates to compositions comprising such hCG-encoding nucleic acid constructs.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention provides tumor-derived extracellular vesicles (EVs) lacking an immune suppressive factor, for example, miR-424, methods of making and methods of use for treating cancer. Further the present invention provide vaccine compositions comprising modified tumor-derived EVs for use in treating secondary tumors.

The invention discloses an immunoenhancer, an immunotherapy medicine composition, a preparation method of the immunotherapy medicine composition and an application of the immunoenhancer and the immunotherapy medicine composition. The immunoenhancer at least comprises interferon and granular cell-macrophage colony stimulating factors, and the immunotherapy medicine composition at least comprises antigen and the immunoenhancer. The immunoenhancer can remarkably enhance the immunity of a body and improve the antigen presenting efficiency of the body, so that the body can establish effective immune activation and response. Strong antibody and cellular immune protection reaction and pathogen removing capacity can be generated, and the immunoenhancer can be applied to therapy of diseases and tumors caused by microorganisms such as viruses and bacteria.

An immunomagnetic composition, a preparation method and a use thereof, and a kit for treating a cancer are provided. The immunomagnetic composition comprises a core layer, a shell layer, and an outerlayer. The shell layer is composed of a composite and encapsulates the core layer. The composite is formed by the combination of fucoidan, oxidized dextran, and a plurality of superparamagnetic iron oxide nanoparticles by hydrophobic interaction. The outer layer comprises at least one antibody that is grated on the shell layer so as to form the outer layer. The immunomagnetic composition is applied to preparation of anti-cancer drugs.

The presently disclosed subject matter relates to tumor infiltrated T cells induced by oncolytic virus (“OV-induced T cells”), methods of making and using said OV-induced T cells for an adoptive T-cell therapy. The presently disclosed subject matter further relates to oncolytic viruses and armed oncolytic viruses, methods of making and using said oncolytic viruses, as well as pharmaceutical compositions and kits comprising said oncolytic viruses.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The invention discloses a PD-L1 CAR structure, a specific structure of a CAR sequence of the PD-L1 CAR structure is as follows: a CD8 alpha leading peptide-PD-L1 scFv-CD8 alpha transmembrane region, aCD137 intracellular costimulatory domain, a CD247 intracellular activation domain. Tumor targeting and T cell double-activation pathway molecules are integrated into a single PD-L1 chimeric receptorgene, so that the feasibility of treating solid tumors by genetically modified T cells is greatly improved, the preparation cost is reduced, and the product can be applied to treatment of PD-L1 high-expression solid tumors, such as lung cancer, liver cancer, colon cancer and the like.

The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

Therapeutic modalities are provided for targeting adoptive cellular therapies to specific sites of disease, involving the use of specific repertoirs of PRR ligands. In effect, innate immune system signaling is provoked so as to facilitate the homing of adoptive immune cells to sites of disease, for example to the site of a solid tumor.

The invention provides improved compositions for adoptive cell therapies for cancers that express the glycoepitope STn on TAG-72.

One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound in any order together or separately. The first compound is an effective amount of a checkpoint inhibitor optionally with at least one pharmaceutically acceptable carrier. The second compound is an effective amount of an Therapeutic Double Stranded RNA (tdsRNA) optionally with at least one pharmaceutically acceptable carrier. The compounds can be administered together or separately. Compositions for the practice of the method are also described.

Use of an IL-1[beta] binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for thetreatment and / or prevention of cancer with at least partial inflammatory basis.

The invention discloses and provides an antigen composed of nine polypeptides from a WT1 protein sequence. According to the antigen, a WT1 target is analyzed through computer software, sequence splitting is carried out on the part, with the best antigenicity, of a protein, and split polypeptides are combined into nine long peptides as antigen sequences. The polypeptide combination disclosed by theinvention has the advantages of better antitumor effect and wider lineage.

The invention provides improved compositions for adoptive cell therapies for cancers that express the glycoepitope STn on TAG-72.

Non-naturally occurring vesicles derived from bacteria, e.g., pathogenic bacteria, methods for making the vesicles, and methods for using compositions of these vesicles are disclosed. Methods of using the vesicles include prevention and / or treatment of bacterial infections. Also provided herein are compositions that include vesicles derived front bacteria and tumor vesicles, methods for making the tumor vesicles, and methods for using the compositions of bacterial vesicles and tumor vesicles. Methods of using the compositions of bacterial vesicles and tumor vesicles include treatment of cancer in a subject. Tumor vesicles may be derived from cancer cells present in the subject to be treated or from a cancer cell line expressing at least one neoantigen. The neoantigen may be specific to the subject and may have been identified by sequencing of the cancer cells from the subject. The neoantigen may be a neoantigen known to be commonly expressed in a particular type of cancer.

The invention discloses a compound for treating colon cancer and application thereof. The compound comprises black phosphorus quantum dots, liposomes, Adpgk peptides and F127 gel; the Adpgk peptides and the black phosphorus quantum dots are wrapped by the liposomes to form Adpgk peptide black phosphorus quantum dot liposomes; the Adpgk peptide black phosphorus quantum dot liposomes are embedded in the F127 gel. According to the invention, the black phosphorus quantum dots with good photothermal effect and Adpgk polypeptides are effectively loaded by the liposomes, so that the combined application of a photothermal method and an immune method is realized; meanwhile, it is found that application of the black phosphorus quantum dots loaded Adpgk polypeptide liposome (Adpgk polypeptide / BPQDs / Liposome) has more advantages in the anti-tumor effect than application of the black phosphorus quantum dots loaded composite liposome, and it is indicated that the anti-tumor effect can be effectively enhanced through combined application of thermal therapy and immunological therapy.

The invention provides a recombinant virus vector, an immune composition containing the same, and a use. The recombinant virus vector comprises a polynucleotide encoding a tumor antigen, and the tumorantigen is one or more selected from a LAGE antigen, a MAGE antigen, or a NY-ESO-1 antigen. A recombinant virus vector vaccine provided by the invention can stimulate tumor-specific immune response,effectively inhibits tumor cell growth, and prolongs the survival time of tumor patients.